Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27890922 | 0.83 | ALDH1A1 (0.46) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL677050 | 0.83 | MEN1 (0.38) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL5355181 | 0.79 | FAAH (0.34) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL2194799 | 0.78 | KDM4E (0.40) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL1397174 | 0.75 | CYP19A1 (0.43) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL3793920 | 0.74 | ALDH1A1 (0.41) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL677051 | 0.73 | TRPV6 (0.40) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL5355185 | 0.72 | CNR2 (0.36) | CNR2FAAHMEN1KMT2AKDM4E | |
| SCHEMBL30986891 | 0.71 | MEN1 (0.41) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1397066 | 0.71 | KDM4E (0.40) | CNR2FAAHMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020780-A1 | STAR-SHAPED POLYMER, PAINT, COATING, AND METHOD FOR PRODUCING STAR-SHAPED POLYMER | DIC CORPORATION (JP) | 2024-02-01 | — | — | WO | disclosed |
| WO-2022236548-A1 | STAR POLYMER, COATING MATERIAL, COATING FILM, AND METHOD FOR PRODUCING STAR POLYMER | DIC CORPORATION (JP) | 2022-11-17 | — | — | WO | disclosed |
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| EP-2539316-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| WO-2016124493-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2016-08-11 | — | — | WO | disclosed |
| EP-2197840-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-1472576-B1 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-2197869-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-2539316-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2013-01-02 | — | — | EP | disclosed |
| EP-1392675-B1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SC HOLDING AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| EP-1472576-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| EP-1392675-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1344109-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003067332-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002098870-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002046507-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
| US-6261738-B1 | LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | CNR2 1117/4885FAAH 1125/4885MEN1 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.